(Q37074284)

18 August 2017

1 reference

title

Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas (English)

1 reference

18 August 2017

1 reference

Elias Drakos

1

1 reference

18 August 2017

George Z Rassidakis

series ordinal

2

1 reference

18 August 2017

L Jeffrey Medeiros

series ordinal

3

1 reference

18 August 2017

publication date

4 February 2008

1 reference

Expert Reviews in Molecular Medicine

18 August 2017

published in

1 reference

18 August 2017

volume

10

1 reference

18 August 2017

page(s)

e4

1 reference

NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Genetic control of cell size

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Drosophila S6 kinase: a regulator of cell size

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

When translation meets transformation: the mTOR story

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Induction of autophagy and inhibition of tumorigenesis by beclin 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Ras, PI(3)K and mTOR signalling controls tumour cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

The hypoxia-induced paralogs Scylla and Charybdis inhibit growth by down-regulating S6K activity upstream of TSC in Drosophila

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Stress and mTORture signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

The coordinate regulation of the p53 and mTOR pathways in cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

The LKB1 tumor suppressor negatively regulates mTOR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

TSC2 mediates cellular energy response to control cell growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

TOR signaling in growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Akt regulates growth by directly phosphorylating Tsc2

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

The phosphoinositide 3-kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Rheb binds and regulates the mTOR kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Rheb is an essential regulator of S6K in controlling cell growth in Drosophila

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Rheb promotes cell growth as a component of the insulin/TOR signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM)

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

The Drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Leucine limitation induces autophagy and activation of lysosome-dependent proteolysis in C2C12 myotubes through a mammalian target of rapamycin-independent signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Tor-mediated induction of autophagy via an Apg1 protein kinase complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Autophagy in health and disease: a double-edged sword

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

mTOR-dependent activation of the transcription factor TIF-IA links rRNA synthesis to nutrient availability

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Ribosome biogenesis and cell growth: mTOR coordinates transcription by all three classes of nuclear RNA polymerases

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Regulation of peptide-chain elongation in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

eIF3: a connecTOR of S6K1 to the translation preinitiation complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Transduction of growth or mitogenic signals into translational activation of TOP mRNAs is fully reliant on the phosphatidylinositol 3-kinase-mediated pathway but requires neither S6K1 nor rpS6 phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Amino acid-induced translation of TOP mRNAs is fully dependent on phosphatidylinositol 3-kinase-mediated signaling, is partially inhibited by rapamycin, and is independent of S6K1 and rpS6 phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Synthesis of the translational apparatus is regulated at the translational level

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

The mTOR pathway in the control of protein synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Regulation of translation initiation by FRAP/mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Upstream and downstream of mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Does the ribosome translate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Growing roles for the mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

mTOR, translational control and human disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Preferential development of pre-B lymphomas with drastically down-regulated N-myc in the E mu-ret transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Defining the role of mTOR in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Yeast TOR (DRR) proteins: amino-acid sequence alignment and identification of structural motifs

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Carboxyl-terminal region conserved among phosphoinositide-kinase-related kinases is indispensable for mTOR function in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

HEAT repeats in the Huntington's disease protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Cell cycle checkpoint signaling through the ATM and ATR kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Inhibitors of the mammalian target of rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

A mammalian protein targeted by G1-arresting rapamycin-receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

A Putative Sirolimus (Rapamycin) Effector Protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

TOR1 and TOR2 are structurally and functionally similar but not identical phosphatidylinositol kinase homologues in yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Downstream effectors of oncogenic ras in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

The AKT kinase is activated in multiple myeloma tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Damaged microtubules can inactivate BCL-2 by means of the mTOR kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Syk-dependent mTOR activation in follicular lymphoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Inhibition of phosphatidylinositol 3'-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Current development of mTOR inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Sirolimus: its discovery, biological properties, and mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin D2, cyclin D3, cyclin-dependent kinase (cdk) 4 and the cdk inhibitor p27

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Anaplastic lymphoma kinase proteins in growth control and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

FKBP12-Rapamycin-associated Protein (FRAP) Autophosphorylates at Serine 2481 under Translationally Repressive Conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

FAT: a novel domain in PIK-related kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

7 January 2021

Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

7 January 2021

Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum.

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

7 January 2021

FKBP12-rapamycin target TOR2 is a vacuolar protein with an associated phosphatidylinositol-4 kinase activity.

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

7 January 2021

JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

7 January 2021

Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

7 January 2021

Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

7 January 2021

Revised NMR assignments for rapamycin

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

7 January 2021

New antitumor substances of natural origin

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

7 January 2021

Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000586

7 January 2021

10.1017/S1462399408000586

Identifiers

DOI

1 reference

18 August 2017

1 reference